Tiny Health secured $33 million in Series B funding to expand its microbiome testing capabilities. The round was led by B Capital with participation from multiple health-focused venture investors. The company is using the financing to scale microbiome diagnostics and testing capacity, reflecting continued investor demand for applied life science diagnostics with clinical relevance. For biotech buyers and healthcare stakeholders, the move underscores how microbiome measurement remains one of the most funded categories within translational health innovation. With more testing volume and broader adoption targets, Tiny Health’s funding signals an effort to move microbiome tools from research-stage workflows toward standardized, scalable services.